Characteristics of patients who received NIV by phenotype
| All phenotypes | ALS-bulbar | ALS-cervical | ALS-lumbar | Flail limb | p Value | |
|---|---|---|---|---|---|---|
| Sample, n | 219 | 58 | 61 | 78 | 22 | |
| Age at NIV initiation, years | 60.8±10.8 | 64.5±10.1 | 59.8±11.3 | 59.9±10.6 | 56.5±9.8 | 0.009* |
| Gender, male | 157 (71.7) | 36 (62.0) | 47 (77.0) | 57 (73.0) | 17 (77.2) | 0.270† |
| Riluzole prescription | 164 (74.9) | 47 (81.0) | 47 (77.0) | 57 (73.0) | 13 (59.0) | 0.224† |
| PEG insertion | 129 (58.9) | 45 (77.5) | 36 (59.0) | 42 (53.8) | 6 (27.2) | <0.001† |
| Time to NIV initiation, months from disease onset | 30.2 (26.0) | 24.5 (16.1) | 30.6 (22.7) | 27.6 (22.8) | 53.2 (47.8) | <0.001* |
Data presented as mean±SD or number (percentage).
*One-way ANOVA.
†χ2 Test.
ANOVA, analysis of variance; ALS, amyotrophic lateral sclerosis;
NIV, non-invasive ventilation; PEG, percutaneous endoscopic gastrostomy.